VIQ Solutions to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
Investors may access a live webcast of the call on the Company's website at www.viqsolutions.com/investors or by dialing 1-888-440-4052 (North America toll-free) or +1-646-960-0827 (international) to be connected to the call by an operator using conference ID number 4983233. Participants should dial in at least 10 minutes prior to the start of the call.
A replay of the webcast will be available on the Company's website through the same link approximately one hour after the conference call concludes.
About VIQ Solutions Inc.
VIQ Solutions is a global provider of secure, AI-driven, digital voice and video capture technology and transcription services. VIQ offers a seamless, comprehensive solution suite that delivers intelligent automation, enhanced with human review, to drive transformation in the way content is captured, secured, and repurposed into actionable information. The cyber-secure, AI technology and services platform are implemented in the most rigid security environments including criminal justice, legal, insurance, government, corporate finance, media, and transcription service provider markets, enabling them to improve the quality and accessibility of evidence, to easily identify predictive insights and to achieve digital transformation faster and at a lower cost.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
14 minutes ago
- Business Wire
AMERICAN WOODMARK INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of American Woodmark Corporation
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of American Woodmark Corporation (NasdaqGS: AMWD) to MasterBrand, Inc. (NYSE: MBC). Under the terms of the proposed transaction, shareholders of American Woodmark will receive 5.150 shares of MasterBrand for each share of American Woodmark that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
14 minutes ago
- Business Wire
Icertis CEO Samir Bodas to Become Executive Chairman; Chief Operating Officer Anand Subbaraman Appointed as CEO
BELLEVUE, Wash.--(BUSINESS WIRE)-- Icertis, the global leader in AI-powered contract intelligence, today announced that its CEO and Co-founder, Samir Bodas, will become Executive Chairman after more than 15 years of visionary leadership. Chief Operating Officer, Anand Subbaraman, has been appointed Chief Executive Officer. Samir co-founded Icertis in 2009 with Monish Darda, growing the business to become the undisputed category leader approaching $350 million in annual recurring revenue. In that time, Samir illuminated the strategic role that contracts play in enterprise-wide digital transformation, drove deep partnerships with hyper-scalers and the largest system integrators, and established contract intelligence as a critical system of record used by more than one third of the Fortune 100. 'In the age of 'AI everything', where technology is transforming both companies and whole industries, Anand's extensive experience in building amazing products, operational depth in delivering to customers at scale, and core values grounded in FORTE make him an ideal fit to take Icertis into the future,' said Samir. 'Over the last 15 years, we have built category-defining products to help our customers derive exceptional value by transforming their end-to-end contracting – the foundation of all commerce. As I focus on my health, the time is right for Anand to step into the CEO role and take Icertis to the next level. I look forward to partnering closely with him as we continue to launch breakthrough innovations.' Anand's 25-year track record of driving strategy and engineering spans global enterprise software companies including Oracle, BrowserStack, and Finastra. During his tenure as COO at Icertis, Anand has expanded his remit across core lines of business while playing a pivotal role in enabling AI innovation and elevating strategic partnerships. Under Anand's direction, Icertis will further its mission of empowering customers to realize the full potential of every business relationship, continue to deliver trusted AI, and enable even more enterprises globally to leverage contracts as strategic drivers of value. 'Enterprise technology sits at a critical inflection point, and Icertis continues to deliver unique and differentiated contact intelligence through our vast data assets, contract-specific AI, agents and co-pilots, and our Contract Intelligence platform to create fast, measurable ROI for customers,' said Anand. 'I am honored to lead Icertis and our incredible team of Icertians to realize the company's bold vision for the future of commerce – powered by contract intelligence.' 'As global commerce is reinvented in today's business landscape, trust and agility in relationships has never been more critical. Icertis is transforming how the world's most vital commercial relationships are negotiated and managed – and setting the standard for innovation at a pivotal moment,' said Penny Pritzker, Lead Independent Icertis Director. 'Icertis is uniquely positioned to lead the next wave of enterprise AI by elevating contracts as one of the most powerful business assets in every industry. I am confident in Anand's ability to take the helm and advance the company's mission.' Contracts are the foundation of every business relationship, establishing the rules for how enterprises buy, sell, and partner to drive their global commerce. Icertis Contract Intelligence creates a single source of truth for relationships, delivering analytics, operations, and performance in one platform to surface profit-powering insights, optimize negotiations, and put contract terms to work post-signature to maximize revenue and savings. About Icertis Icertis delivers AI-powered insights and agentic automation to transform static contracts into strategic enterprise advantage. The Icertis Contract Intelligence platform revolutionizes how enterprises manage their customer, supplier, and partner relationships, enabling businesses to grow revenue, control costs, mitigate risk, and ensure compliance. Today, more than one third of the Fortune 100 trust Icertis to realize the full potential of millions of business relationships in more than 90 countries around the world.
Business Wire
14 minutes ago
- Business Wire
BostonGene Named 'AI-based Drug Discovery Solution of the Year' in 2025 AI Breakthrough Awards Program
BUSINESS WIRE)-- BostonGene, a leader in AI-powered solutions for drug discovery and development, has been honored with the 'AI-based Drug Discovery Solution of the Year' award in the 8 th annual AI Breakthrough Awards program. AI Breakthrough is a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market. 'BostonGene's AI platform delivers powerful, accurate and reproducible biological signatures that represent an enhanced approach drug development - bringing precision oncology closer to clinical reality.' BostonGene's breakthrough AI platform is transforming oncology research and drug development by integrating high throughput tissue analytics with genomic, transcriptomic and clinical data. This multimodal approach creates biological signatures, leading to improved target identification and enhanced patient stratification for clinical trials. As part of its integrated solution, BostonGene's novel AI-driven platform combines advanced digital pathology capabilities–such as pixel-level analysis of whole slide images–with molecular and clinical data. The insights that BostonGene's platform delivers sharpen the precision of predictive biomarker and therapeutic target discovery. 'BostonGene's AI platform stands out for its ability to synthesize clinical, molecular and imaging data–generating comprehensive, actionable insights that drive drug development and precision oncology,' said Steve Johansson, managing director, AI Breakthrough. 'BostonGene's AI platform delivers powerful, accurate and reproducible biological signatures that represent an enhanced approach drug development - bringing precision oncology closer to clinical reality.' 'Through our strategic collaborations with leading cancer centers and pharmaceutical companies, we are integrating advanced technology like AI into oncology care,' said Ferran Prat, PhD, JD, Chief Commercial Officer at BostonGene. 'We're grateful to AI Breakthrough for the 'AI-based Drug Discovery Solution of the Year' award, and we will continue to focus on using innovative AI-powered solutions to revolutionize personalized cancer treatment, expedite drug development and improve patient outcomes.' The AI Breakthrough Awards shine a spotlight on the boldest innovators and most impactful technologies that are leading the charge in AI across a comprehensive set of categories, including Generative AI, Computer Vision, AIOps, Agentic AI, Robotics, Natural Language Processing, industry-specific AI applications and many more. This year's program attracted more than 5,000 nominations from over 20 different countries, underscoring the explosive growth and global importance of AI as a defining technology of the 21st century. About BostonGene Corporation BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit About AI Breakthrough Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the AI Breakthrough Awards program is devoted to honoring excellence in Artificial Intelligence technologies, services, companies and products. The AI Breakthrough Awards provide public recognition for the achievements of AI companies and products in categories including Generative AI, Machine Learning, AI Platforms, Robotics, Business Intelligence, AI Hardware, Computer Vision and more. For more information visit Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
